Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Carsten Haagen Nielsen"'
Autor:
Bjarke Follin, Cecilie Hoeeg, Ingrid Hunter, Simon Bentsen, Morten Juhl, Jacob Kildevang Jensen, Tina Binderup, Carsten Haagen Nielsen, Rasmus Sejersten Ripa, Jens Kastrup, Annette Ekblond, Andreas Kjaer
Publikováno v:
Diagnostics, Vol 13, Iss 2, p 268 (2023)
An increasing number of patients are living with chronic ischemic cardiomyopathy (ICM) and/or heart failure. Treatment options and prognostic tools are lacking for many of these patients. Our aim was to investigate the prognostic value of imaging ang
Externí odkaz:
https://doaj.org/article/553816c9f2dd4bc9abb265082e198552
Autor:
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, Camilla Christensen, Carsten Haagen Nielsen, Andreas Kjaer
Publikováno v:
Pharmaceutics, Vol 14, Iss 6, p 1284 (2022)
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (177Lu)-ba
Externí odkaz:
https://doaj.org/article/d6b2d80148e042e8a5115977f0392f07
Autor:
Eva Gravesen, Maria Lerche Mace, Anders Nordholm, Jacob Hofman-Bang, Keith Hruska, Carsten Haagen Nielsen, Andreas Kjær, Klaus Olgaard, Ewa Lewin
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190820 (2018)
Hyperphosphatemia and vascular calcification are frequent complications of chronic renal failure and bone morphogenetic protein 7 (BMP7) has been shown to protect against development of vascular calcification in uremia. The present investigation exam
Externí odkaz:
https://doaj.org/article/03d0a929aa8748dba833d55b47227ed9
Autor:
Camilla Bardram Johnbeck, Mette Munk Jensen, Carsten Haagen Nielsen, Anne Mette Fisker Hag, Ulrich Knigge, Andreas Kjaer
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91387 (2014)
The mTOR inhibitor everolimus has shown promising results in some but not all neuroendocrine tumors. Therefore, early assessment of treatment response would be beneficial. In this study, we investigated the in vivo and in vitro treatment effect of ev
Externí odkaz:
https://doaj.org/article/070490d67a484a21bcbdc989d649808b
Autor:
Sigrid Cold, Moritz Braig, Trine Bjoernbo Engel, Maria Zeiler Alfsen, Maria Nikoline Kristiansen, Lotte Kellemann Kristensen, Andreas Kjaer, Carsten Haagen Nielsen
Publikováno v:
Cancer Research. 83:4680-4680
Breast cancer is the most prevalent cancer in women worldwide. 30% of breast cancer patients develops metastases at distant organs, with 10-20% of these patients developing brain metastases. The median survival time for patients with brain metastases
Autor:
Marina, Simón, Jesper Tranekjær, Jørgensen, Harshvardhan A, Khare, Camilla, Christensen, Carsten Haagen, Nielsen, Andreas, Kjaer
Publikováno v:
Pharmaceutics. 14(6)
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (
Autor:
Sigrid Cold, Saif AL-Haidar, Jennifer Solgaard Joergensen, Trine Bjoernbo Engel, Frederikke Petrine Fliedner, Lotte Kellemann Kristensen, Andreas Kjaer, Carsten Haagen Nielsen
Publikováno v:
Cancer Research. 82:1657-1657
Background: Syngeneic mouse tumor models are widely used and effective tools to evaluate efficacy of novel anti-cancer therapies. They are often implanted subcutaneously in a microenvironment that is unrelated to the site of origin. This can be probl
Autor:
Christina, Schjoeth-Eskesen, Carsten Haagen, Nielsen, Søren, Heissel, Peter, Højrup, Paul Robert, Hansen, Nic, Gillings, Andreas, Kjaer
Publikováno v:
Journal of Labelled Compounds & Radiopharmaceuticals
The human epidermal growth factor receptor-2 (HER2) is overexpressed in 20-30% of all breast cancer cases, leading to increased cell proliferation, growth and migration. The monoclonal antibody, trastuzumab, binds to HER2 and is used for treatment of
Autor:
Henrik Gutte, Adam Espe Hansen, Helle Hjorth Johannesen, Andreas Ettrup Clemmensen, Jan Henrik Ardenkjær-Larsen, Carsten Haagen Nielsen, Andreas Kjær
Publikováno v:
Capital Region of Denmark
University of Copenhagen
Technical University of Denmark Orbit
Gutte, H, Hansen, A E, Johannesen, H H, Clemmensen, A E, Ardenkjær-Larsen, J H, Nielsen, C H & Kjær, A 2015, ' The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer ' American Journal of Nuclear Medicine and Molecular Imaging, vol. 5, no. 5, pp. 548-60 .
University of Copenhagen
Technical University of Denmark Orbit
Gutte, H, Hansen, A E, Johannesen, H H, Clemmensen, A E, Ardenkjær-Larsen, J H, Nielsen, C H & Kjær, A 2015, ' The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer ' American Journal of Nuclear Medicine and Molecular Imaging, vol. 5, no. 5, pp. 548-60 .
In recent years there has been an immense development of new targeted anti-cancer drugs. For practicing precision medicine, a sensitive method imaging for non-invasive, assessment of early treatment response and for assisting in developing new drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::06d312137095ea61e6a563f2d5b75ac8
https://research.regionh.dk/en/publications/the-use-of-dynamic-nuclear-polarization-13cpyruvate-mrs-in-cancer(bcd56989-a75e-4e73-a43f-b7088abb83a0).html
https://research.regionh.dk/en/publications/the-use-of-dynamic-nuclear-polarization-13cpyruvate-mrs-in-cancer(bcd56989-a75e-4e73-a43f-b7088abb83a0).html